Skip to main content

Advertisement

SpringerLink
Log in

Update on adult attention-deficit/hyperactivity disorder

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent and highly morbid neurobehavioral disorder afflicting children, adolescents, and adults throughout the world. This article discusses the clinical assessment of adult ADHD, reviews the results of recent adult ADHD treatment studies with an emphasis on medications currently approved by the US Food and Drug Administration, and discusses the clinical management and monitoring of ADHD pharmacotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fayyad J, de Graaf R, Kessler R, et al.: Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007, 190:402–409.

    Article  PubMed  CAS  Google Scholar 

  2. Kessler RC, Adler L, Barkley R, et al.: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163:716–723.

    Article  PubMed  Google Scholar 

  3. Birnbaum HG, Kessler RC, Lowe SW, et al.: Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005, 21:195–206.

    Article  PubMed  Google Scholar 

  4. Kessler RC, Lane M, Stang PE, et al.: The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med 2008, 21:1–11.

    Article  Google Scholar 

  5. de Graaf R, Kessler RC, Fayyad J, et al.: The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 2008 May 27 (Epub ahead of print).

  6. Kessler RC, Adler LA, Ames M, et al.: The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005, 35:245–256.

    Article  PubMed  Google Scholar 

  7. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.

    Google Scholar 

  8. Kessler RC, Adler LA, Gruber MJ, et al.: Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) screener in a representative sample of health plan members. Int J Methods Psychiatr Res 2007, 16:52–65.

    Article  PubMed  Google Scholar 

  9. Yeh CB, Gau SS, Kessler RC, et al.: Psychometric properties of the Chinese version of the adult ADHD Self-Report Scale. Int J Methods Psychiatr Res 2008, 17:45–55.

    Article  PubMed  Google Scholar 

  10. Reinhardt MC, Benetti L, Victor MM, et al.: Is age-at-onset criterion relevant for the response to methylphenidate in attention-deficit/hyperactivity disorder? J Clin Psychiatry 2007, 68:1109–1116.

    Article  PubMed  CAS  Google Scholar 

  11. Biederman J, Mick E, Spencer T, et al.: An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr 2006, 11:390–396.

    PubMed  Google Scholar 

  12. Pliszka S, AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 46:894–921.

    Article  PubMed  Google Scholar 

  13. Wilens TE, Rostain AL: Pharmacologic management with methylphenidate in adults with attention-deficit/hyperactivity disorder: an analysis of safety, efficacy, and dosing. Presented at the 2007 annual meeting of the American Psychiatric Association. San Diego; May 2007.

  14. Biederman, J, Boellner SW, Childress A, et al.: Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007, 62:970–976.

    Article  PubMed  CAS  Google Scholar 

  15. Biederman J, Mick E, Surman C, et al.: A randomized, placebo-controlled trial of OROS-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006, 59:829–835.

    Article  PubMed  CAS  Google Scholar 

  16. Medori R, Ramos-Quiroga JA, Casas M, et al.: A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008, 63:981–989.

    Article  PubMed  CAS  Google Scholar 

  17. Weisler RH, Biederman J, Spencer TJ, et al.: Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006, 11:625–639.

    PubMed  Google Scholar 

  18. Wilens T: Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs 2003, 63:2395–2411.

    Article  PubMed  CAS  Google Scholar 

  19. Faraone SV, Spencer T, Aleardi M, et al.: Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol 2004, 54:24–29.

    Article  CAS  Google Scholar 

  20. Spencer TJ, Adler LA, McGough JJ, et al.: Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007, 61:1380–1387.

    Article  PubMed  CAS  Google Scholar 

  21. Adler L, Dietrich A, Reimherr FW, et al.: Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry 2006, 18:107–113.

    Article  PubMed  Google Scholar 

  22. Michelson D, Adler LA, Spencer T, et al.: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003, 53:112–120.

    Article  PubMed  CAS  Google Scholar 

  23. Adler LA, Spencer TJ, Milton DR, et al.: Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 2005, 66:294–299.

    PubMed  CAS  Google Scholar 

  24. Adler LA, Spencer TJ, Williams DW, et al.: Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008 April 30 (Epub ahead of print).

  25. Adler LA, Goodman DW, Kollins SH, et al.: Efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Presented at the 2008 annual meeting of the American Psychiatric Association. Washington, DC; May 2008.

  26. Olfson M, Marcus SM, Zhang HF, et al.: Adult ADHD and stimulant dosing in the community setting. Presented at the 2007 annual meeting of the American Psychiatric Association. San Diego; May 2007.

  27. Faraone S: Comparing the efficacy of medications for ADHD using meta-analysis. Presented at the 2006 annual meeting of the American Psychiatric Association. Toronto; May 2006.

  28. Adler LA, Morrill M, Reingold B: d-Methylphenidate augmentation of extended-release stimulant therapy in ADHD. Presented at the 2006 annual meeting of the American Psychiatric Association. Toronto; May 2006.

  29. Robison RJ, Reimherr FW, Marchant BK, et al.: Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis. J Clin Psychiatry 2008, 69:213–221.

    Article  PubMed  Google Scholar 

  30. Kratochvil CJ, Newcorn JH, Arnold LE, et al.: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005, 44:915–924.

    Article  PubMed  Google Scholar 

  31. Wilens TE, Adler LA, Weiss MD, et al.: Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008, 96:145–154.

    Article  PubMed  CAS  Google Scholar 

  32. Biederman J, Monuteaux M, Spencer T, et al.: Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008, 165:597–603.

    Article  PubMed  Google Scholar 

  33. Nissen SE: ADHD drugs and cardiovascular risk. N Engl J Med 2006, 354:1445–1448.

    Article  PubMed  CAS  Google Scholar 

  34. Biederman J, Spencer TJ, Wilens TE, et al.: Treatment of ADHD with stimulant medications: response to Nissen Perspective in the New England Journal of Medicine. J Am Acad Child Adolesc Psychiatry 2006, 45:1147–1150.

    Article  PubMed  Google Scholar 

  35. Vetter VL, Elia J, Erickson C, et al.: Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008, 117:2407–2423.

    Article  PubMed  Google Scholar 

  36. Vitiello B: Understanding the risk of using medications for ADHD with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am 2008, 17:459–474.

    Article  PubMed  Google Scholar 

  37. Gelperin K: Studying Cardiovascular Risk With Drug Treatments of ADHD. Rockville, MD: US Food and Drug Administration Drug Safety and Risk Management Advisory Committee; 2006.

    Google Scholar 

  38. Biederman J, Mick E, Surman C, et al.: Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 2007, 7:49.

    Article  PubMed  CAS  Google Scholar 

  39. Neibler G, Wilens T, Weisler R, et al.: Evaluation of cardiovascular effects of lisdexamfetamine dimesylate treatment in adults with attention-deficit/hyperactivity disorder. Presented at the 2008 annual meeting of the American Psychiatric Association. Washington, DC; May 2008.

  40. Berwaerts J, Orman C, Berry SA, et al.: Cardiovascular safety data from a long-term open-label study of OROS MPH in adults with ADHD. Presented at the 2008 annual meeting of the American Psychiatric Association. Washington, DC; May 2008.

Download references

Author information

Authors and Affiliations

  1. Clinical and Research Program in Pediatric Psychopharmacology, 185 Alewife Brook Parkway, Suite 2000, Cambridge, MA, 02138, USA

    Paul Hammerness

Authors
  1. Paul Hammerness
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig Surman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katherine Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Hammerness.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hammerness, P., Surman, C. & Miller, K. Update on adult attention-deficit/hyperactivity disorder. Curr Neurol Neurosci Rep 8, 484–489 (2008). https://doi.org/10.1007/s11910-008-0077-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-008-0077-z

Keywords

Search

Navigation